Results 71 to 80 of about 39,591 (271)

Ocriplasmin in the treatment of vitreomacular traction in a patient with central retinal vein occlusion. a case report [PDF]

open access: yes, 2018
Aim: To investigate the efficacy of intravitreal injection of ocriplasmin (JETREA®) in the treat-ment of vitreomacular traction (VMT). Materials and Methods: An 81-year-old man with VMT associated with central retinal vein occlusion in his left eye, was ...
Antonio Esposito, Raffaele   +3 more
core   +2 more sources

Topical anesthesia for intravitreal injection [PDF]

open access: yesExpert Opinion on Drug Delivery, 2012
In-office intravitreal delivery of medications has currently become the standard of care treatment for a variety of ocular conditions, including age-related macular degeneration, diabetic eye disease, cystoid macular edema, and vascular occlusions. Patients undergoing an intravitreal injection procedure most commonly experience pain at the injection ...
Jonathan, Gambrell, Shlomit, Schaal
openaire   +2 more sources

GHRHR Deficiency Enhances Retinal Ganglion Cell Survival and Visual Functions in Experimental Glaucoma by Inhibiting Ferroptosis

open access: yesAdvanced Science, EarlyView.
Glaucoma, a major cause of blindness, involves retinal ganglion cell (RGC) degeneration. This study shows growth hormone‐releasing hormone receptor (GHRHR) deficiency preserves RGC survival and restores vision, unlike activation which only aids survival.
Yan Tong   +24 more
wiley   +1 more source

Follow-up rates for patients needing regular intravitreal therapy in rural north-western Western Australia

open access: yesRural and Remote Health, 2021
Introduction: Regular intravitreal injections are an important treatment for significant vision impairment caused by diabetic macular oedema. Barriers to intravitreal treatment for rural Australian patients include travel time to appointments ...
Andrew Nguyen, Angus Turner
doaj   +1 more source

Smart Nanotechnologies for Multimodal Neuromodulation and Brain Interfacing

open access: yesAdvanced Science, EarlyView.
Recent advances in smart nanotechnologies are expanding the toolbox for brain interfacing, from wireless neuromodulation and high‐resolution sensing to targeted delivery within the central nervous system. By combining responsive nanomaterials with bioinspired design, these platforms enable multimodal interactions with neurons and glia, while also ...
Tommaso Curiale   +6 more
wiley   +1 more source

Corticosteroid implants for chronic non-infectious uveitis. [PDF]

open access: yes, 2016
BACKGROUND: Uveitis is a term used to describe a heterogeneous group of intraocular inflammatory diseases of the anterior, intermediate, and posterior uveal tract (iris, ciliary body, choroid).
Brady, Christopher J   +7 more
core   +2 more sources

A Viscous DES‐AAV‐Foxo1 Delivery System With High Transfection Efficiency for the Treatment of Corneal Endothelial Dysfunction by Restoring Mitochondria‐ER Contacts

open access: yesAdvanced Science, EarlyView.
High glucose triggers corneal endothelial dysfunction by impairing FOXO1‐mediated ITPR1 transcription, leading to disrupted mitochondria‐associated membrane (MAM) integrity and defective ER‐to‐mitochondria Ca2+ transfer. This study develops an innovative viscous DES‐AAV‐Foxo1 delivery system with enhanced transfection efficiency. This non‐invasive gene
Hongran Zhao   +10 more
wiley   +1 more source

The Role of Steroids in the Management of Macular Edema from Retinal Vein Occlusion

open access: yesOftalʹmologiâ, 2019
Aim: To analyze the effectiveness of intravitreal injection of an anti-VEGF agent (ranibizumab) and an dexametazon implant for the intravitreal injection, in real clinical life. Patients and Methods.
M. V. Budzinskaya   +4 more
doaj   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova   +5 more
wiley   +1 more source

Soluble Epoxide Hydrolase Inhibition for Ocular Diseases: Vision for the Future [PDF]

open access: yes, 2019
Ocular diseases cause visual impairment and blindness, imposing a devastating impact on quality of life and a substantial societal economic burden. Many such diseases lack universally effective pharmacotherapies.
Corson, Timothy W., Park, Bomina
core   +1 more source

Home - About - Disclaimer - Privacy